Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Dryer, Peter D ^a   Limketkai, Berkeley N ^a   Martin, Christina M ^a   Ma, Gang ^a   Sherman, Kenneth E ^a   Taylor, Lynn E ^b   Mayer, Kenneth H ^b   Jamieson, Denise J ^c   Blackard, Jason T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

C316Y; HCV; NS5B

Indexed keywords

CYSTEINE; NONSTRUCTURAL PROTEIN 5B; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; SERINE; THREONINE; TYROSINE; ANTIVIRUS AGENT; ENZYME INHIBITOR; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; SEQUENCE ANALYSIS; VIRUS REPLICATION; ADULT; AMINO ACID SEQUENCE; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MISSENSE MUTATION; MOLECULAR GENETICS; SEQUENCE ALIGNMENT;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ALIGNMENT; VIRAL NONSTRUCTURAL PROTEINS;

EID: 73949099483     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp328     Document Type: Article

References (13)

1. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61: 1205-16.
2. Bavisotto L, Wang CC, Jacobson IM et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. In: Abstracts of the American Association for the Study of Liver Diseases, Boston, MA, 2007. Abstract 49.
3. Chen CM, He Y, Lu L et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 2007; 51: 4290-6.
4. Villano S, Howe A, Raible D et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. In: Abstracts of the American Association for the Study of Liver Diseases, Boston, MA, 2006. Abstract 1127.
5. Howe AY, Cheng H, Johann S et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 2008; 52: 3327-38.
6. Smith D, Warren D, Vlahov D et al. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort of human immunodeficiency virus infection in US women. Am J Epidemiol 1997; 146: 459-69.
7. Stover C, Smith D, Schmid D et al. Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis 2003; 187: 1388-96.
8. Dutartre H, Bussetta C, Boretto J et al. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues. Antimicrob Agents Chemother 2006; 50: 4161-9.
9. Blackard JT, Dryer PD, Limketkai BN et al. Interpatient and intrapatient variability in the HCV polymerase (NS5B) among high-risk women. In: Abstracts of the Fourth International HIV and Hepatitis Co-Infection Workshop, Madrid, Spain, 2008. Abstract 39.
10. Collins JA, Thompson MG, Paintsil E et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004; 78: 603-11.
11. Havlir DV, Eastman S, Gamst A et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 7: 7894-9.
12. McCown MF, Rajyaguru S, Le Pogam S et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604-12.
13. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008; 48: 1769-78.